×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 2 Track 3: Commercial/Clinical Case Studies – Synthetic Oligos
Session Chair(s)
Firoz Antia, PhD
Head of Oligonucleotide Development
Biogen, United States
Session 2 Track 3: Commercial/Clinical Case Studies – Synthetic Oligos
Speaker(s)
Oligonucleotide Solution API: Navigating the Regulatory Landscape
Chris Chorley
Biogen, United States
Associate Director, Regulatory Affairs CMC
Regulatory CMC Learnings and Perspectives from recent RNAi Filings
Representative Invited
Alnylam Pharmaceuticals, United States
Speaker
Representative Invited
Federal Institute for Drugs and Medical Devices, Germany
Speaker
Representative Invited
FDA, United States
Have an account?